Raymond James Financial
QTTB icon

Raymond James Financial’s Q32 Bio QTTB Stock Holding History

Raymond James Financial’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,746
Closed -$16K – 6873
2025
Q2 		$16K Hold
10,746
– – ﹤0.01% 5696
2025
Q1 		$17.7K Hold
10,746
– – ﹤0.01% 4727
2024
Q4 		$37K Buy
+10,746
New +$339K ﹤0.01% 4649

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
TOCUITCONY
Trustees of Columbia University in the City of New York New York $891M AUM 17.3% 1-Year Est. Return

Raymond James Financial's QTTB Position: Q3 2025 in Review

Raymond James Financial sold out of Q32 Bio (QTTB) in Q3 2025, closing a stake of 10,746 shares — an estimated $16K sold.

Raymond James Financial first reported a position in QTTB in Q4 2024 and held it in 3 quarters. The position peaked at $37K in Q4 2024. 53 funds tracked by Wall St. Rank hold QTTB as of Q3 2025.

  • Raymond James Financial reported no remaining Q32 Bio position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 10,746 Q32 Bio shares in Q3 2025, an estimated $16K.
  • Raymond James Financial first reported a position in Q32 Bio in Q4 2024 and held it in 3 quarters.
  • Raymond James Financial's Q32 Bio position peaked at $37K in Q4 2024.
  • 53 funds tracked by Wall St. Rank held Q32 Bio as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.